Cerevel Therapeutics Holdings (CERE) - Stock & Dividends

Cerevel Therapeutics Holdings, Inc. is a company in the United States focusing on developing therapies for diseases related to neuroscience. One of its key products in development is Emraclidine, a positive allosteric modulator being tested in phase 1b clinical trials to potentially treat schizophrenia.

Furthermore, Cerevel Therapeutics is working on Darigabat, another positive allosteric modulator, currently in Phase 2 proof-of-concept trial for patients with drug-resistant focal onset seizures in epilepsy. It is also being tested in a phase 1 trial to address panic symptoms.

In addition to these, the company has other significant products like Tavapadon, a dopamine D1/D5 partial agonist in phase 3 clinical trial for Parkinson's disease, and CVL-354, a selective kappa-opioid receptor antagonist intended for major depressive disorder and substance use disorder.

Moreover, Cerevel Therapeutics is exploring an M4 agonist program for treating psychosis and related conditions, along with developing a PDE4 inhibitor to target psychiatric, neuroinflammatory, and other disorders.

Established in 2018 and based in Cambridge, Massachusetts, more information about Cerevel Therapeutics Holdings, Inc. can be found on their official website: https://www.cerevel.com.